6201, Penn Therapeutics CRS
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Doyle, Jamie
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Recruiting
2
48
US, RoW
Selgantolimod, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV Infections
11/26
05/27
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Terminated
2
44
US
Letermovir Oral Tablet, Prevymis
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Active, not recruiting
2
90
US
CMV-MVA Triplex, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections, Vaccine
11/24
10/25
NCT06066957: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Recruiting
2
80
US
Letermovir 480 MG [Prevymis]
University of Pennsylvania, Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Transplant-Related Disorder
08/26
08/26
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Doyle, Jamie
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Recruiting
2
48
US, RoW
Selgantolimod, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV Infections
11/26
05/27
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Terminated
2
44
US
Letermovir Oral Tablet, Prevymis
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Active, not recruiting
2
90
US
CMV-MVA Triplex, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections, Vaccine
11/24
10/25
NCT06066957: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Recruiting
2
80
US
Letermovir 480 MG [Prevymis]
University of Pennsylvania, Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Transplant-Related Disorder
08/26
08/26
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29

Download Options